NYSE · WST
Healthcare · Medical - Instruments & Supplies
$365.00
Up+$9.67 (+2.72%)
Updated Sep 16, 2026, 12:50 PM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
WST closed at $365.00 after 20 trading sessions, up 5.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $355.02 | $370.67 | $354.65 | $365.00 | 981.89K |
| Sep 14, 2026 | $349.94 | $356.61 | $345.15 | $355.20 | 625.56K |
| Sep 11, 2026 | $343.87 | $351.96 | $341.675 | $346.23 | 541.79K |
| Sep 10, 2026 | $333.57 | $344.92 | $331.99 | $344.25 | 653.06K |
| Sep 9, 2026 | $337.63 | $340.475 | $336.10 | $336.94 | 473.17K |
| Sep 8, 2026 | $335.51 | $342.34 | $334.04 | $337.75 | 580.99K |
| Sep 4, 2026 | $339.76 | $342.67 | $339.76 | $339.97 | 364.08K |
| Sep 3, 2026 | $343.97 | $345.50 | $338.445 | $342.73 | 242.27K |
| Sep 2, 2026 | $338.85 | $346.00 | $338.85 | $342.63 | 323.73K |
| Sep 1, 2026 | $341.83 | $342.6675 | $337.85 | $338.65 | 482.81K |
| Aug 31, 2026 | $336.25 | $342.59 | $335.51 | $341.11 | 615.6K |
| Aug 28, 2026 | $344.51 | $345.87 | $336.13 | $337.47 | 496.41K |
| Aug 27, 2026 | $350.00 | $352.05 | $346.08 | $346.09 | 365.99K |
| Aug 26, 2026 | $347.97 | $353.12 | $346.25 | $349.92 | 440.22K |
| Aug 25, 2026 | $353.75 | $354.78 | $348.22 | $348.48 | 383.76K |
| Aug 24, 2026 | $350.48 | $354.48 | $348.84 | $353.32 | 473.31K |
| Aug 21, 2026 | $357.87 | $359.18 | $349.70 | $353.08 | 511.13K |
| Aug 20, 2026 | $349.17 | $360.285 | $347.99 | $353.77 | 588.4K |
| Aug 19, 2026 | $348.28 | $356.36 | $348.28 | $352.79 | 511.06K |
| Aug 18, 2026 | $346.47 | $350.04 | $345.06 | $346.59 | 274.25K |
The latest Smart Investors Daily articles mentioning WST.
WST research
Company profile and research snapshot.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Buy | — |
| Aug 3, 2026 | Citigroup | Buy | — |
| Jul 27, 2026 | Evercore ISI Group | Outperform | — |
| Jul 13, 2026 | BNP Paribas | Outperform | — |
| Jul 9, 2026 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
West Pharmaceutical Services, Inc. (WST) Wells Fargo 21st Annual Healthcare Conference September 10, 2026 8:45 AM EDTCompany ParticipantsRobert McMahon -...
Benzinga · Sep 9, 2026
UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
Yahoo · Sep 7, 2026
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
Yahoo · Sep 7, 2026
Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WST.
